Lilly Expands Gate Bioscience Deal to Over $870 Million
Lilly adds a target to its Gate Bioscience molecular gates collaboration, with total potential value above $870M. What is and is not disclosed.
FHD-909 Discontinued: Foghorn and Lilly End SMARCA2 Program
FHD-909 discontinued: Foghorn and Lilly will not advance the SMARCA2 inhibitor after Phase 1 data, and Foghorn is cutting about 40% of its workforce.